Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Retevmo
|
| gptkbp:activities |
inhibitor of TRK, RO S1, and ALK
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:legislation
gptkb:FDA gptkb:United_States |
| gptkbp:class |
tyrosine kinase inhibitor
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 Phase 3 |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:discontinued |
gptkb:battle
|
| gptkbp:effective_date |
2019-08-15
|
| https://www.w3.org/2000/01/rdf-schema#label |
entrectinib
|
| gptkbp:indication |
metastatic cancer
locally advanced cancer |
| gptkbp:ingredients |
C22 H24 N4 O2 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors other medications affecting liver enzymes |
| gptkbp:invention |
patented
|
| gptkbp:is_available_on |
gptkb:brand
generic |
| gptkbp:is_monitored_by |
blood pressure
liver function tests complete blood count |
| gptkbp:is_used_for |
treatment of solid tumors
treatment of non-small cell lung cancer |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
Rozlytrek
|
| gptkbp:population |
adults
pediatric patients |
| gptkbp:provides_information_on |
ASCO guidelines
ESMO guidelines NCCN guidelines |
| gptkbp:research_focus |
cancer therapy
targeted therapy precision medicine |
| gptkbp:side_effect |
dizziness
fatigue nausea diarrhea rash constipation drug interactions elevated liver enzymes peripheral edema serious adverse reactions |
| gptkbp:storage |
room temperature
protected from light protected from moisture |
| gptkbp:targets |
gptkb:NTRK_gene_fusions
ALK gene fusions RO S1 gene fusions |
| gptkbp:weight |
396.57 g/mol
|